Australia markets open in 5 hours 38 minutes

InspireMD, Inc. (NSPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.4900+0.0200 (+0.81%)
As of 01:58PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.4700
Open2.5000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.4900 - 2.5350
52-week range1.8100 - 3.8500
Volume2,183
Avg. volume33,380
Market cap62.151M
Beta (5Y monthly)0.95
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

    Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of the CGuard™ Prime Carotid Stent System anticipated in H1 2025, if approved TEL AVIV, Israel, and MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent S

  • GlobeNewswire

    InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

    - Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2024, to be held May 28-31 - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s CGUARDIANS II clinical trial for Transcarotid Artery Revascularization (TCAR), as well a

  • GlobeNewswire

    InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

    -Conference call and webcast to be held at 8:30 a.m. EDT-TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open. Management will host a conference call and webcast with the investment community at 8:30